Mirza MR, Tandaric L, Henriksen JR, Mäenpää J, Christensen RD, Waldstrøm M, Lindemann K, Roed H, Auranen A, Akslen LA, Thomsen LCV, Lindberg SN, Madsen K, Bjørge L(2024) NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer Gynecol Oncol, 188, 103-110(in press) DOI 10.1016/j.ygyno.2024.06.017, PubMed 38943691
Luijten MMW, van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, Boll D, Werner HMJ, van Lonkhuijzen LRCW, Yigit R, Krakstad C, Witteveen PO, Galaal K, van Ginkel AA, Bignotti E, Weinberger V, Sweegers S, Eriksson AGZ, Keizer DM, van de Stolpe A, Romano A, Pijnenborg JMA, European Network For Individualized Treatment In Endometrial Cancer(2024) Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma Cancers (Basel), 16(11) DOI 10.3390/cancers16112084, PubMed 38893205
Davidson B, Skeie-Jensen T, Holth A, Hausladen S(2024) Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma Int J Gynecol Pathol(in press) DOI 10.1097/PGP.0000000000001030, PubMed 38847524